Potentiation by treatment with reserpine of alpha 2-adrenoceptor-mediated contractions of rat tail artery

Transient supersensitivity to alpha-adrenoceptor agonists, and distinct hyper-reactivity to vasopressin and angiotensin II after denervation of rat tail artery

BACKGROUND AND PURPOSE

Vascular 'denervation' hyper-reactivity has generally been investigated 1-2 weeks after administration of chemicals that temporarily prevent transmitter release, but do not necessarily inactivate the neuronal noradrenaline transporters (NETs). We have investigated the reactivity of rat tail arteries over longer periods after removing the terminals by surgical denervation.

EXPERIMENTAL APPROACH

Two and 7 weeks after denervation, myography was used to assess contractions of isolated arterial segments to phenylephrine, methoxamine, clonidine, vasopressin and angiotensin II (AII). Denervation was confirmed by lack of tyrosine hydroxylase immunoreactive nerve terminals.

KEY RESULTS

The NET inhibitor, desmethylimipramine, increased the pEC(50) for phenylephrine in control, but not denervated arteries after both 2 and 7 weeks. Relative to controls, pEC(50)s for phenylephrine (with desmethylimipramine), methoxamine, clonidine and vasopressin were increased at 2 but not 7 weeks after denervation. The pEC(50) for phenylephrine in the absence of desmethylimipramine was greater than control after both 2 and 7 weeks' denervation. The maximum contraction to vasopressin was larger than in controls at 2 but not 7 weeks after denervation, whereas contractions to AII were markedly enhanced at both time points.

CONCLUSIONS AND IMPLICATIONS

Increased vascular reactivity to alpha(1)- and alpha(2)-adrenoceptor agonists, and vasopressin is transient following denervation. After 7 weeks, increased reactivity to phenylephrine can be entirely accounted for by the loss of NETs. Maintained supersensitivity to AII indicates that denervation differentially and selectively affects vascular reactivity to circulating vasoconstrictor agents. This might explain persistent vasoconstriction in denervated skin of humans after nerve injuries.

The p44/42 mitogen-activated protein kinase cascade is involved in the induction and maintenance of astrocyte stellation mediated by protein kinase C

The mitogen-activated protein kinase (MAPK) is known to be involved in the differentiation of various types of cells. To understand the role of p44/42 MAPK (ERK1/2) in astrocyte differentiation, we investigated the effects of U0126 and PD98059, specific inhibitors of the MAPK-activating enzyme MEK, on astrocyte morphology in culture. Cultured rat cortical astrocytes exhibited flattened, polygonal morphology in the absence of stimulation, but differentiated into process-bearing stellate cells in response to the membrane-permeable cyclic AMP analog dibutyryl cyclic AMP (dBcAMP) or the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA). dBcAMP-induced astrocyte stellation was not affected by MEK inhibitors, while PMA-induced astrocyte stellation was significantly blocked by U0126 (0.1-10 microM) and PD98059 (10-30 microM). Western blot analysis with an antibody specific for phosphorylated ERK1/2 revealed that PMA, but not dBcAMP, induced phosphorylation of ERK1/2 in a time- and concentration-dependent manner. The PMA-induced astrocyte stellation and ERK1/2 phosphorylation were blocked by specific PKC inhibitors, GF-109203X (0.01-1 microM) and calphostin C (1 microM). In addition, when U0126 or PD98059 was added after treatment with PMA, stellate astrocytes returned to polygonal. These results suggest that the MEK/ERK cascade is involved in the induction and maintenance of astrocyte stellation mediated by PKC, but not by cyclic AMP signaling.

L-glutamate suppresses amyloid beta-protein-induced stellation of cultured rat cortical astrocytes

Alzheimer's amyloid beta-protein (Abeta) has been reported to potentiate glutamate toxicity in neurons, but very little is known about interaction between Abeta and glutamate in astrocytes. Therefore, in the present study, we investigated the effects of Abeta and glutamate on morphology of astrocytes. Cultured rat cortical astrocytes exhibited polygonal morphology in the absence of stimulation and differentiated into process-bearing stellate cells following exposure to Abeta (20 microM). L-Glutamate (30-1,000 microM) had no effect on astrocyte morphology in the absence of stimulation but strongly suppressed Abeta-induced stellation. The suppressive effect of L-glutamate on Abeta-induced stellation was not mimicked by glutamate receptor agonists and not blocked by glutamate receptor antagonists. In contrast, the suppressive effect of L-glutamate was mimicked by D- and L-aspartate and transportable glutamate uptake inhibitors. These results suggest that Abeta-induced astrocyte stellation is suppressed by a mechanism related to glutamate transporters.

Adenosine stimulates stellation of cultured rat cortical astrocytes

We investigated the effect of adenosine on astrocyte morphology by using cell cultures prepared from the cerebral cortices of neonatal rats. Cultured rat cortical astrocytes exhibited flattened, polygonal morphology in the absence of stimulation, but differentiated into process-bearing stellate cells in response to adenosine (1-1000 microM). Adenosine-induced astrocyte stellation was abolished by treatment with microtubule inhibitors, colchicine and paclitaxel, indicating the involvement of cytoskeletal elements. The effect of adenosine was mimicked by other adenosine receptor agonists, and blocked by adenosine receptor antagonists and guanosine 5'-O-(2-thiodiphosphate), indicating that the effect of adenosine is mediated by G protein-coupled adenosine receptors. Although adenosine receptors are known to be linked to adenylate cyclase or phospholipase C, adenosine did not change intracellular cyclic AMP level nor intracellular Ca2+ concentration in astrocytes. Alternatively, adenosine-induced stellation was abolished by tyrosine phosphatase inhibitors, orthovanadate and phenylarsine oxide, suggesting that adenosine causes astrocyte stellation through tyrosine dephosphorylation. Adenosine may function as a factor regulating astrocyte differentiation.

Developmental changes in cyclic AMP-stimulated stellation of cultured rat cortical astrocytes

When cultured astrocytes are treated with agents that elevate intracellular cyclic AMP, they become process-bearing stellate cells. In the present study, we investigated possible developmental changes of astrocyte stellation induced by beta-adrenoceptor stimulaton. Cultured astrocytes were prepared from the cerebral cortices of embryonic day 18 (E18) and postnatal day 2 (P2) rats. Treatment with the beta-adrenoceptor agonist isoproterenol induced stellation in P2 astrocytes more potently and rapidly than in E18 astrocytes. Isoproterenol-stimulated increase in cellular cyclic AMP levels was very similar in E18 and P2 astrocytes. The membrane-permeable cyclic AMP analog dibutyryl cyclic AMP induced stellation in P2 astrocytes more potently and rapidly than in E18 astrocytes. Stellation induced by the protein kinase C activator phorbol ester was not different between E18 and P2 astrocytes. These results suggest that beta-adrenoceptor-mediated astrocyte stellation increases during development and that this change is attributed to the development of mechanisms downstream from cyclic AMP production.

Role of different subtypes of adrenoceptors in pressor responses to catecholamines released from sympathetic nerve endings

The role of alpha 1- and alpha 2-adrenoceptors in the vascular effects of catecholamines, either released locally from sympathetic nerve endings (e.g., in vascular smooth muscle) or derived from the adrenal medulla or administered intravenously, was studied using selective antagonists of these adrenoceptors. The ganglionic stimulant dimethylphenyl-piperazinium-iodide (DMPP) exerted dual actions on blood pressure: a rapid and short-term pressor reaction (phase I) resulting from catecholamine release elicited by ganglion stimulation, followed by a more sustained blood pressure elevation (phase II) resulting from the circulating catecholamines released from the adrenal medulla. The selective alpha 2-adrenoceptor, but a not subtype selective, antagonist 7,8-(methylenedioxi)-14-alpha-alloberbane HCl (CH-38083) (50-100 micrograms/kg, IV) significantly (p < 0.05) inhibited the pressor effects of epinephrine and norepinephrine given intravenously and phase II of the DMPP-induced pressor reaction. Idazoxan exerted similar effects, but at higher doses (400-600 micrograms/kg, IV). WB-4101 (50-100 micrograms/kg, IV) and BRL-44408 (2-3 mg/kg, IV), two selective alpha 2A-adrenoceptor antagonists, had the same activity as CH-38083, except did not inhibit the pressor effect of intravenously administered norepinephrine. The alpha 2B-adrenoceptor selective antagonist, ARC-239 (150 micrograms/kg, IV) did not influence phase II of DMPP-induced pressor reaction. Prazosin (200 micrograms/kg, IV), an antagonist of alpha 1 and alpha 2B-adrenoceptors, reduced blood pressure, the pressor response to intravenously administered epinephrine, and phase I of the DMPP-induced pressor effect. In addition, it completely inhibited the pressor responses to DMPP remaining after administration of CH-38083. These results suggest that the postsynaptically located alpha 1- and alpha 2(A and B)-adrenoceptors are involved in pressor response to norepinephrine and epinephrine, and are sensitive and accessible to catecholamines released locally from the axon terminals, and from the circulation to a different extent. These results may have great therapeutical importance in hypertension, for which the involvement of both a high level of circulating and locally released catecholamines may be indicative of the usefullness of a combination (alpha 1- and alpha 2-adrenoceptors- and Ca-channel-blocking agents) therapy.

Regional difference in sympathetic neurotransmitter- and Ca2+ channel-mediated responses in rat vas deferens

1. Pharmacological properties were compared in the epididymal and prostatic portions of the rat vas deferens. 2. Contractile response to norepinephrine (NE) was larger in the epididymal portion, in spite of the smaller diameter in this region. In contrast, contraction evoked by ATP or alpha,beta-methylene ATP (alpha,beta-mATP) was larger in the prostatic portion. The sensitivities to NE but not to alpha,beta-mATP are different in these portions. 3. ATP or NE facilitated the contraction induced by the other agonist, suggesting that they cooperatively elicit smooth muscle contraction. This cooperation was observed in both portions. 4. Neither the contraction elicited by the addition of Ca2+ to smooth muscle depolarized with 63.7 mM extracellular K+ nor the relaxation by nifedipine of the depolarized smooth muscle precontracted with 1.8 mM extracellular Ca2+ was regionally different. However, Bay k 8644 elicited contraction only in the epididymal portion. A combination of 5 mMK+ with Bay k 8644 also caused oscillatory contraction in the prostatic portion. 5. A radioligand binding study was performed using the microsomal fraction prepared separately from these portions. Both the dissociation constant and the maximum binding for 3H-nimodipine were smaller in the epididymal fraction than in the prostatic fraction. 6. These results suggest that 1. the NE-elicited contraction is more pronounced in the epididymal portion, 2. the purinoceptor-mediated contractions along the vas deferens are less heterogeneous, and 3. although the sensitivity to Bay k 8644 is higher in the epididymal portion, Ca2+ channel-mediated responses are not regionally different when they are fully activated.

Alpha 2-adrenoceptors and the regulation of glucose, insulin and amylin levels in diabetic rats

The effects of the selective alpha 2-adrenoceptor agonist UK 14.304 on glucose, insulin and amylin levels were examined in neonatal streptozotocin-induced diabetic rats. UK 14.304 (0.03 to 0.3 mg/kg i.p.) induced a dose-dependent reduction of both insulin and amylin levels in normal rats while UK 14.304 at 0.03 mg/kg had already a maximal effect in diabetic rats. Amylin/insulin molar ratios rose after UK 14.304 administration in diabetic rats but remainded constant in normal rats. The alpha 2-adrenoceptor antagonist deriglidole (3 mg/kg i.p.) slightly increased insulin and amylin levels in the two groups of rats but glucose levels were more markedly decreased in diabetic rats. Deriglidole completely antagonized UK 14.304 (0.1 mg/kg i.p.)-induced changes thereby normalizing amylin/insulin molar ratios in diabetic rats. These results suggest that insulin and amylin are both under inhibitory control via alpha 2-adrenoceptor though the responses may be differentially regulated. It is further suggested that diabetes in the neonatal streptozotocin-induced rat model is associated with a hypersensitivity of the pancreas to alpha 2-adrenoceptor stimulation.

Acute and chronic effects of reserpine on biochemical and functional parameters of central and peripheral alpha 2-adrenoceptors

The specific binding of the agonist, [3H]UK 14304, and of the antagonist, [3H]RX 821002, to rat brain membranes, as well as clonidine-induced mydriasis, clonidine-induced inhibition and idazoxan-induced stimulation of brain 3,4-dihydroxyphenylalanine (DOPA) synthesis, and clonidine and UK 14304-induced inhibition of twitch responses in the vas deferens were used to evaluate the affinity and sensitivity of central and peripheral alpha 2-adrenoceptors after various treatments with reserpine. Treatment with reserpine (0.25 mg/kg s.c., every 48 h) for 4, 11 and 18 days induced consistent and significant increases in the affinity (KD values) of [3H]UK 14304 for the cortical alpha 2-adrenoceptor with no change in receptor density. Chronic treatment with reserpine also resulted in a greater affinity of (-)-adrenaline for the high-affinity state of the alpha 2-adrenoceptor when the catecholamine competed with the binding of [3H]RX 821002 to cortical membranes. In line with these radioligand binding data, various functional responses mediated by central and peripheral alpha 2-adrenoceptors were found to be potentiated after repeated treatment with reserpine. Thus, the inhibitory alpha 2-autoreceptor that modulates the synthesis of brain noradrenaline and the central postsynaptic inhibitory alpha 2-adrenoceptor that induces mydriasis displayed greater responses in vivo after chronic treatment with reserpine. Short-term and chronic treatments with reserpine also increased the sensitivity of peripheral presynaptic alpha 2-adrenoceptors in the vas deferens.(ABSTRACT TRUNCATED AT 250 WORDS)

Blockade by calmodulin inhibitors of Ca2+ channels in smooth muscle from rat vas deferens

1. Effects of three compounds which are used as calmodulin inhibitors (trifluoperazine, W-7 and calmidazolium) on Ca2+ channels were investigated in smooth muscle from rat vas deferens. 2. All three calmodulin inhibitors relaxed the smooth muscle precontracted by a high concentration of KCl (63.7 mM). The order of potency for the relaxation was trifluoperazine > W-7 > calmidazolium. 3. In binding studies using a microsomal fraction of vas deferens, all these calmodulin inhibitors displaced specific [3H]-nimodipine binding. Trifluoperazine and W-7 inhibited the binding at concentrations that relaxed the smooth muscle whereas calmidazolium inhibited at concentrations much lower than those necessary for muscle relaxation. 4. Ba2+ current flowing through voltage-gated Ca2+ channels was measured under whole-cell voltage-clamp conditions in isolated smooth muscle cells. The Ba2+ current was suppressed by the three calmodulin inhibitors in the concentration-range where inhibition of [3H]-nimodipine binding was observed. Neither voltage-dependence nor the inactivation time course of Ba2+ current were affected by these compounds. 5. The results suggest that the calmodulin inhibitors directly block Ca2+ channels in the smooth muscle cells. The channel inhibition by trifluoperazine and W-7, but perhaps not that by calmidazolium, may be responsible for the muscle relaxation observed with these compounds.